Drug Development

5 articles

Cosmos & Space

Lilly's oral obesity drug shows promising safety and tolerability

Lilly's experimental oral obesity drug, aleniglipron, helped patients lose up to 12.

Aram Sarkisian·June 7, 2026

Bacteriophages, microscopic viruses, actively targeting and neutralizing harmful bacteria in a symbolic representation of phage therapy's potential against antimicrobial resistance.

Health & Medicine

Phage therapy adoption hurdles: Regulatory and clinical challenges.

By 2050, antimicrobial resistance (AMR) is projected to cause 10 million deaths worldwide annually.

Marcus Cole·June 4, 2026

Microscopic view of cancer cells being targeted by a glowing therapeutic agent, representing Revolution Medicines' experimental drug.

Cosmos & Space

Revolution Medicines' Experimental Pancreatic Cancer Drug Shows Promise

Revolution Medicines' experimental drug daraxonrasib doubled the median overall survival for patients with metastatic pancreatic cancer to 13.2 months in its pivotal Phase 3 trial.

David Grossman·May 31, 2026

Symbolic handshake between Pfizer and Innovent Biologics representatives, signifying a major global pharmaceutical partnership for drug pipeline development.

Cosmos & Space

Pfizer partners with Innovent Biologics for drug pipeline

Pfizer has committed up to $10.5 billion to a collaboration with Innovent Biologics in China to advance a pipeline of 12 novel therapies.

David Grossman·May 30, 2026

A dimly lit laboratory with a microscope, symbolizing the disappointment of a failed Parkinson's drug trial.

Cosmos & Space

Merck Halts Parkinson's Drug Program After Phase 3 Setback

Merck's Parkinson's drug, preladenant, was discontinued in 2026 after Phase 3 trials showed it was no more effective than a placebo.

Aram Sarkisian·May 22, 2026